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“‘It is hard to be brave’, said Piglet, sniffing slightly, ‘when you’re only a very
small animal’. Rabbit, who had begun to write very busily, looked up and said: ‘It
is because you are a very small animal that you will be useful in the adventure
before us’.”
Alan Alexander Milne, Winnie-the-Pooh and All, All,

All
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Osteomyelitis, one of the oldest documented diseases, the descriptions of which date back to
times of Hippocrates [1], is an illness particularly prevalent among elderly, diabetics,
children and indigenes of Third World countries. Although morbidity due to chronic bone
infection has drastically dropped from the pre-penicillin era, down to approximately 3% in
the last 20 years [2], it is still high on the global scale and the disease continues to be
challenging to treat [3]. Furthermore, the number of hip and knee replacement procedures
performed in the USA has doubled in the past decade, while the number of the reported
cases of bone infection accompanying those has been increasing in proportion with the
number of surgeries performed [4], signifying the anticipated increase in the incidence rate
of this illness in the future.
The standard therapy for osteomyelitis has been based on the combination of repetitive
intravenous or oral delivery of antibiotics over the period of a few weeks to a few months,
depending of the severity of the infection, and surgical debridement of necrotic bone [5].
This clinical approach has had its obvious disadvantages, predominantly in terms of:
•

Systemic administration of antibiotics and its side effects;
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•

Frequent inaccessibility of the infected zone to the blood flow and the resulting low
concentration of the therapeutic around it, potentially inducing pathogenic
resistance to the antibiotic therapy;

•

Irretrievable bone loss;

•

Cost–ineffectiveness.

For this reason, more advanced antibiotic delivery options have been actively sought since
the early 1970s, when the first carriers for local delivery in the treatment of osteomyelitis,
composed of poly(methyl methacrylate), were clinically applied [6]. Even though
poly(methyl methacrylate) beads still present the gold standard for the local delivery of
antibiotics to bone cavities, their downsides are numerous, including:
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•

Non-biodegradability;

•

Proneness to biofilm formation;

•

Need to be surgically removed;

•

Tendency to exhibit burst release;

•

Inconsistent release profiles, a corollary of the typically manual presurgical
loading;

•

Limited clinical data in support thereof [7].

The problem with calcium sulfates and collagen fleeces, two other commonly used antibiotic
carriers in the clinic, comes from their high resorption rate and non-immunogenicity,
respectively.
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Nanosized calcium phosphates (CAPs), in contrast, present potentially the most natural
choice for antibiotic delivery platforms in bone therapy. First of all, nano-CAP is the natural
mineral component of bone. CAP crystals in bone, stiff but brittle, have the role of imparting
sufficient compressive strength to intrinsically tough collagen fibers, thus yielding a
composite material that is both strong and tough. Second, CAPs are bioactive, bioresorptive
and osteo-conductive, that is, conducive to bone growth. Third, they are one of the safest
and most bio-compatible nanomaterials assessed for toxicity so far [8]. Fourth, they could be
prepared in nanoform and in a variety of morphologies using simple and eco-friendly
precipitation procedures [9]. Fifth, they are good adsorbents of biomolecules, which
predisposes them to be used as the stationary phase in chromatographic columns [10] and is a
prerequisite for achieving satisfying loading capacities. Finally, CAPs exist in a dozen or so
different phases, whose solubility varies from highly soluble mono-CAPs to moderately
soluble di-CAPs to sparsely soluble amorphous CAP and tri-CAPs to very sparsely soluble
octa-CAP and hydroxyapatite, the CAP phase found in bone, dentin and enamel. The control
of stochiometry of CAP thus makes it possible to tune its degradation rate and, therefore, the
drug release kinetics. This effect has been employed to vary in vitro drug release time scale
from hours to months [11].
Target areas in the body and types of the drugs delivered require specific release patterns for
the optimal therapeutic effect to be achieved. For example, β-lactam antimicrobials are timedependent, requiring prolonged presence in the target zone, while quinolones and
aminoglycosides are concentration-dependent [12]. Then, vasculature of the target tissue
affects the drug-clearance period, which is why different release profiles prove to be optimal
for highly vascular trabecular bone and less vascular cortical bone. Easily achievable
tunability of the release rate thus presents a highly desirable property of the drug carrier.
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The capability of CAPs to augment the osteogenic response of osteoblasts, the bone-building
cells, has been demonstrated on multiple occasions [13,14]. Ca2+ and HxPO4x−3 ions released
upon the degradation of these compounds can also stimulate osteoblastic differentiation [15]
and proliferation [16] and be used as ionic ingredients for the new bone formation. With
systemic and repetitive administration of antibiotics and surgical debridement being two
central problematic aspects of traditional therapies, an ideal delivery carrier would ensure
not only local and sustained release of the drug, but also the induction of osteogenesis, so as
to minimize, if not wholly eliminate, the surgical removal of affected bone. Patients with
diabetic neuropathy are, for example, prone to develop osteomyelitis of the forefoot, which
often leads to minor amputation [17]; however, with the development of osteogenic carriers
that could revitalize the diseased bone, such clinical cases could be coped with in a manner
less traumatic for the patient.
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A critical intrinsic downside of CAPs comes from the fact that intracrystalline impregnation
with the drug via co-precipitation cannot be achieved, as in the case of polymers, which
limits the loading mechanism to adsorption only and inevitably leads to burst release.
Sustained release from CAPs is, however, accomplishable and seems to be contingent on the
formation of compact blocks and encapsulation of the drug in the pores between the
particles, so that the dissolution of the carrier proceeds along the block boundaries, while the
bulk of the drug is being internally protected. This aggregation state, however, does not
favor clinical injectability, a limitation that requires optimal additives to stabilize the surface
drug layer and at the same time prevent particle coalescence.
These and similar deficiencies could be transcended by the usage of CAPs as the base for
composite nanoparticles, the concept towards which the field of nanoscience unstoppably
streams. Coating of CAP core with a layer of a poly(α-hydroxy ester), such as poly(lactideco-glycolide), whose degradation rate itself could be tuned from a few years to a few weeks
depending on the lactide-to-glycolide ratio, is an option to:
•

Stabilize the surface-bound drug layer;

•

Prevent the burst release;

•

Possibly produce multiple-stage release profiles that may additionally boost the
antimicrobial activity of the drug/carrier composite.
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Coating chitosan/tri-CAP composites with poly(ε-caprolactone) has thus mitigated the burst
release and promoted zero-order kinetics for the release of vancomycin during the first 6
weeks [18]. Another important limitation of CAPs, difficult surface functionalization, a
consequence of their ionic nature, which dictates that the surface layers would undergo rapid
reorganization via dissolution/reprecipitation phenomena in ionic media, could be similarly
overcome by coating the ceramic particles with chemically bondable polymeric layers.
Through a series of chemical steps, polymeric coatings could further be conjugated with
various targeting, solubilizing or therapeutic ligands [19]. Another interesting feature of the
combinations of alkaline CAP phases, such as hydroxyapatite or octa-CAP, with acidic
poly(α-hydroxy esters), comes from their ability to compensate intense pH changes that
follow the degradation of each of the two phases individually. This effect may explain why
the addition of demineralized bone particles to poly(lactide-co-glycolide) was able to reduce
inflammation, fibrous tissue encapsulation, and foreign body giant cell response [20].
CAPs, like most ceramics, possess a broad spectrum of possible stochiometries and
structures, which could be, in theory, correlated with a similar, though largely unexplored,
breadth of properties and applications. Although chemistry of CAPs has been intensively
studied for the last century, known facts about it still resemble the tip of an iceberg. Not only
is our knowledge of the mechanism of their formation, in biological milieus and simple
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reaction settings alike, still filled with vast gaps, but numerous other segments of their
structure – property – function chain have yet to be elucidated. In the end, alongside all its
qualities, CAP could be considered as the abovementioned Piglet in the kingdom of
inorganic chemistry. What nature wished to teach us by choosing this pale, fragile, rough,
crumbly and cheap compound as the ingredient of the structural basis of our physical beings
is an open door to poetic insights that we will leave to the imagination of the reader and avid
researchers of this remarkable material.
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